Flu Vaccine Protects Against Six Different Influenza Viruses

Image

A novel nanoparticle vaccine that combines two major influenza proteins is effective in providing broad, long-lasting protection against influenza virus in mice, showing promise as a universal flu vaccine.

The double-layered nanoparticle vaccine contains the influenza virus proteins matrix protein 2 ectodomain (M2e) and neuraminidase (NA). Mice were immunized with the nanoparticle vaccine before being exposed to influenza virus, and they were protected against six different strains of the virus.

“This nanoparticle antigen combination conferred mice with strong cross protection. “It can protect mice from different strains of influenza virus. Each season, we have different flu strains that affect us. By using this approach, we hope this nanoparticle vaccine can protect humans from different strains of influenza virus.

Influenza, a contagious respiratory illness caused by influenza viruses, is a leading cause of death by infection. Seasonal flu vaccines are insufficient to prevent influenza outbreaks, and developing a universal influenza vaccine is the ideal strategy for eliminating public health threats of influenza epidemics and pandemics. A universal influenza vaccine would eliminate the need for vaccinations each season and offers universal protection against all influenza strains.

The influenza virus protein M2e is found in all influenza virus strains, with each strain having a very similar version, and the protein has mutated very slowly over time. The protein NA is found on the surface of influenza virus and has also mutated much slower than other influenza proteins. This double-layered nanoparticle vaccine uses M2e as its core, and NA is coated on the surface. mice were exposed to one of six influenza virus strains after receiving the nanoparticle vaccine by intramuscular injection. The vaccine proved to have long-lasting immune protection, which was unchanged against viral challenges up to four months after immunizations.

The Journal publishes papers/articles of or related to immune system, immunological disorders, hypersensitivity, adjuvants, auto immune disorders and allergic diseases.

It is of immense pleasure to invite Researchers to this inaugural issue for “Journal of Clinical Immunology and Allergy.”

The Journal Considers Editorial, letter, case reports, short communications, original and review articles from leading scientists and scholars around the world in all areas of food, nutrition, biochemistry, physiology, pathology and medicine.

Authors can directly submit the article through online link: http://www.imedpub.com/submissions/insights-allergy-asthma-bronchitis.html or as an attachment to this E-mail: clinicalimmunol@medicineinsights.com

The articles once published can be accessed freely.

Media Contact
Sana George
Journal Manager
Clinical Immunology and Allergy
Email: clinicalimmuno@clinicalmedicaljournals.com
WhatsApp: +1-947-333-4405